Detalles de la búsqueda
1.
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
N Engl J Med;
388(10): 898-912, 2023 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36884323
2.
Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study.
Cancer;
2024 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38703010
3.
GOunder/Desmoid Tumor Research Foundation DEsmoid Symptom/Impact Scale (GODDESS©): psychometric properties and clinically meaningful thresholds as assessed in the Phase 3 DeFi randomized controlled clinical trial.
Qual Life Res;
32(10): 2861-2873, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37347393
4.
Effect of Additives on the Surface Morphology, Energetics, and Contact Resistance of PEDOT:PSS.
ACS Appl Mater Interfaces;
15(31): 38143-38153, 2023 Aug 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37499172
5.
Synthesis of PEDOT:PSS Brushes Grafted from Gold Using ATRP for Increased Electrochemical and Mechanical Stability.
ACS Macro Lett;
12(12): 1718-1726, 2023 Dec 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38052039
6.
Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy.
Cancer Chemother Pharmacol;
77(2): 405-12, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26791869
7.
Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.
Cancer Chemother Pharmacol;
74(5): 1047-55, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25212536
Resultados
1 -
7
de 7
1
Próxima >
>>